Dr. Evens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
195 Little Albany Street
New Brunswick, NJ 08901Phone+1 732-235-2465Fax+1 732-235-8094- Is this information wrong?
Summary
- I am an international clinical expert in the field of lymphoid malignancies, with research interests including the study of novel therapeutic agents, biomarkers, predictive modeling, and the implementation of personalized medicine. The National Institutes of Health (NIH) has continuously funded my research since 2005. This has resulted in 200+ manuscripts in peer-reviewed publications, 350+ research abstracts presented at national and international cancer research symposiums (including 60+ plenary/oral presentations), and 40+ book chapters with an emphasis on biology, prognosis, treatment, and health outcomes.
Administratively, as Associate Director for clinical services at Rutgers Cancer Institute, I facilitate clinical operations and oversee the integration of multidisciplinary programs. As Medical Director of the Oncology Service Line and Oncology Lead for the Combined Medical Group for RWJBarnabas Health (RWJBH), I work to further the mission of the State’s only NCI-designated Comprehensive Cancer Center, supervising all providers and clinical operations to deliver innovative, high-quality, integrated cancer care across 16 acute care hospitals and the associated oncology practices throughout the State of New Jersey. As AV Chancellor for Clinical Innovation and Data Analytics at Rutgers Health, I work closely with RWJBH system leadership to advance innovative and dynamic clinical decision support systems via evidence-based practices.
Nationally, I am a core member of the Hodgkin Lymphoma Working Group for the National Institutes of Health and National Cancer Institute (NCI); Vice-Chair of the Lymphoma Committee for the ECOG-ACRIN NCI research group; co-chair of the Big Ten Cancer Research Consortium lymphoma committee; a recent Board of Trustees member for the Leukemia & Lymphoma Society, New Jersey Chapter; and a re-elected member and the current Chair-Elect of the esteemed North American Scientific Advisory Board (SAB) for the Lymphoma Research Foundation.
Education & Training
- Rutgers Business SchoolMBA, 2020 - 2022
- Northwestern University The Feinberg School of MedicineMSc, Clinical Investigation, 2001 - 2003
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
- Advocate Health Care/Advocate Lutheran General HospitalResidency, Internal Medicine, 1996 - 2000
- Chicago College of Osteopathic Medicine at Midwestern UniversityClass of 1996
- Saint Joseph's CollegeB.S., Biochemistry, Magna cum laude, 1987 - 1991
Certifications & Licensure
- NJ State License 2017 - 2025
- MA State License 2010 - 2019
- IL State License 1996 - 2011
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctor In Cancer Care Jerseys Best, 2023
- Ted Marousas Award Rutgers Business School, 2022
- Top Doctors In Cancer Care Jersey's Best, 2022
- Join now to see all
Clinical Trials
- Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2004 Apr 01
- Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL Start of enrollment: 2003 Oct 28
- Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2004 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.Karmali, R., Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Kl...> ;Blood Advances. 2024 Apr 9
- Harnessing multi-source data for individualized care in Hodgkin Lymphoma.Rodday, A., Maurer, M., Parsons, S., Upshaw, J., Scharman, C., Cui, Z., Cao, Y., Tiger, Y., Evens, A.> ;Blood Reviews. 2024 Jan 14
- Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model.Sullivan, M., White, R., Dashnamoorthy Ravi, Kanetkar, N., Fridman, I., Ekenseair, A., Konry, T., Evens, A.> ;Cell Death & Disease. 2024 Jan 9
- Join now to see all
Journal Articles
- FDG-PET Imaging for Hodgkin Lymphoma: Current Use and Future ApplicationsKostakoglu L and Evens AM, Clinical Advances in Hematology & Oncology, 1/1/2014
- A Phase I/II Trial of Bortezomib Combined Concurrently with Gemcitabine for Relapsed or Refractory DLBCL and Peripheral T-cell LymphomasEvens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, Van Besien KM, Gordon LI, Smith SM, British Journal of Haematology, 8/8/2013
- Intergroup Study Evaluates Outcomes of Elderly vs Younger Patients Treated for Advanced Hodgkin LymphomaEvens AM, ASCO Post, 7/15/2011
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- The Novel 2nd Generation Proteasome Inhibitor MLN9708 Induces Redox- and MAPK-Dependent Cell Death in Hodgkin Lymphoma Cell and T-cell Lymphoma Cell Lines and Human Ly...Dashnamoorthy R, Kandela I, Bhalla S, Zaretsky I, Galloway J, Mazar A, Evens AM, Ninth International Symposium on Hodgkin’s Lymphoma, Cologne, Germany, 10/1/2013
- The Histone Deacetylase Inhibitor (HDACi) Abexinostat): Significant Activity in Relapsed/Refractory Follicular Lymphoma (FL).AM Evens, et al, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
- The Novel 2nd Generation Proteasome Inhibitor MLN9708 Induces Redox and MAPK-Dependent Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and Hum...R Dashnamoorthy and AM Evens, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
- Join now to see all
Lectures
- Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Other
- Multicenter Analysis of Outcomes of Lymphoma in Pregnancy.Evens AM, The ASCO Post
http://www.ascopost.com/issues/november-15,-2013/multicenter-analysis-of-outcomes-of-lymphoma-in-pregnancy.aspx
11/15/2013 - Editor: Advances in the Management of Lymphoma.Evens AM, Highlights from the 12th International Conference on Malignant Lymphoma
http://www.educationalconcepts.net/online-activity-event.aspx?PUID=15367
8/1/2013 - Lymphoma Think Tank.Evens AM, Research to Practice
http://2013researchtopractice.createsend4.com/t/ViewEmail/y/6C47615520E337F6/C2DC492DCE06367514399806BE9B4083
7/1/2013 - Join now to see all
Authored Content
- SOHO 2021: An Update of Lymphoma Treatments in Five PartsSeptember 2021
- Lymphoma Research Foundation Facebook Live Chat10/22/2017
Press Mentions
- Investigators Develop Model to Predict Overall Survival in Adults Diagnosed with Advanced Stage Hodgkin LymphomaDecember 9th, 2022
- Pallawi Torka, MD, on Treating Hodgkin Lymphoma When There Is a Dacarbazine ShortageJune 28th, 2022
- First-Recorded Treatment of Pregnant Lymphoma Patient with Checkpoint InhibitorApril 19th, 2022
- Join now to see all
Grant Support
- Delineation of the molecular heterogeneity underlying treatment failure in follicular lymphomaLeukemia and Lymphoma Society (LLS) Translational Research Program (TRP)2019–2022
- Artificial, Humanized Stem Cell NichesNational Institutes of Health2018–2022
- An integrated acoustofluidic droplet sorting platform for dynamic monitoring of cell-cell interactions and functional phenotyping at single cell levelNIH/NCI2018–2022
- Classification of poor-risk relapsed Non Hodgkin Lymphoma subtypesORIEN NOVA2019–2021
- An integrated microfluidic platform for multidimentional analysis and validation of novel drug combinations for NK cell based immunotherapyNIH2018–2021
- Computing, Optimizing, and Evaluating Quantitative Cancer Imaging BiomarkersNIH/NCI2015–2020
- MAP Kinase Signaling in Lymphoma: A Novel Therapeutic ParadigmNCI2012–2017
- Computerized Quantitative Imaging Assessment of Tumor BurdenNCI/NIH2010–2016
- Research Training in OncologyNCI1981–2014
- Impact Of Lifestyle With Tumor Pathways And Microenvironment On Lymphoma SurvivalNational Cancer Institute2010
- Impact Of Lifestyle With Tumor Pathways And Microenvironment On Lymphoma SurvivalNational Cancer Institute2009–2010
- Targeting The Mitochondria To Treat Lymphoma And MyelomaNational Cancer Institute2005–2009
- NU 02h8: A Phase I Trial Of Redox Regulation In Patients With Relapsed NHLNational Center For Research Resources2004–2007
Committees
- Vice-Chair, Lymphoma Committee, ECOG/ACRIN 2019 - Present
Professional Memberships
- Member
- Member
External Links
- Linkedinhttps://www.linkedin.com/in/andrew-m-evens-do-msc-facp-751ba541/
- CINJ Researchhttps://www.cinj.org/research/evens-laboratory-research-overview
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: